Zymergen Stock Investors Could Receive Cash Payouts From $125 Million IPO Securities Settlement

Investors who purchased Zymergen Inc. stock traceable to its April 2021 initial public offering may be entitled to cash compensation from a $125 million settlement. The class action lawsuit alleges company executives and underwriters misled investors about Zymergen’s commercial prospects before its share price collapsed. You must submit a valid claim by October 11, 2026, to receive a payment.

Understanding the $125 Million Zymergen IPO Class Action Lawsuit

When synthetic biology firm Zymergen Inc. went public in April 2021, it raised hundreds of millions of dollars from everyday investors expecting a groundbreaking tech-bio enterprise. However, court documents filed in the U.S. District Court (Wang v. Zymergen Inc., et al., Case No. 5:21-cv-06028-PCP) tell a very different story.

The class action lawsuit alleges that Zymergen’s offering documents contained misleading statements and omitted critical facts regarding the commercial viability of its key products and internal growth projections. Just months after the IPO, Zymergen made revelations that sent its stock tumbling from its $31 initial offering price down to $8.25 per share by August 4, 2021. Shareholders experienced massive financial losses as a result.

To resolve these serious allegations, several former Zymergen officers and directors, the investment banks that underwrote the IPO, and multiple venture capital firms agreed to pay $125 million into a settlement fund for affected shareholders. Zymergen itself filed for Chapter 11 bankruptcy protection in October 2023 and is not a financial contributor to this specific settlement.

The settling defendants continue to deny all claims of liability, wrongdoing, or fault. They agreed to the $125 million payout solely to eliminate the substantial expense, distraction, and uncertainty of prolonged court battles.

Who Is Eligible for a Cash Payment from the Settlement?

You may be eligible to claim a cash recovery if you purchased or acquired Zymergen Inc. common stock between April 21, 2021, and August 3, 2021, inclusive, traceable to the registration statement issued for the company’s April 2021 IPO.

This class action settlement covers a broad range of everyday people and institutional buyers. Eligible claimants include:

• Individual Investors: Anyone who bought shares during the class period through an individual brokerage account or direct holding.

• Joint Claimants: Spouses or co-investors who purchased stock jointly (both parties must sign the official claim form).

• Investment Vehicles: Mutual funds, exchange-traded funds (ETFs), hedge funds, 401(k) retirement plans, and other employee benefit accounts.

• Estate Representatives: Executors and legal administrators acting on behalf of deceased shareholders.

Whether you held your stock directly or through a broker like Robinhood, Charles Schwab, Fidelity, or Vanguard, your transactions qualify for evaluation under the settlement allocation formula. However, if your ultimate calculated recognized loss is $0 or if your calculated total payout works out to less than $10, no check will be issued due to administrative processing thresholds.

How Much Money Can You Expect to Receive?

The total recovery pool created by the settling defendants stands at $125 million. However, the precise cash payout you receive will depend on how many shares you bought, when you bought them, whether you sold them before or after August 4, 2021, and the total number of valid claims filed across all investors.

According to notice documents released by the claims administrator, the estimated average gross distribution is approximately $6.21 per share before administrative expenses, service awards, and legal fees. Class counsel intends to request up to $37.5 million in attorneys’ fees (30% of the total fund) and up to $3 million in litigation expenses.

After accounting for these requested legal fees and court costs, the net average distribution is estimated to be approximately $4.20 per share.

The settlement administrator uses a specific formula to measure financial harm:

• Shares Sold Before Aug. 4, 2021: Your recognized loss is calculated as the lesser of your purchase price minus the sale price, or $31 (the IPO price) minus the sale price.

• Shares Sold On/After Aug. 4, 2021 (or Still Held): Your recognized loss is calculated as the smallest of: your purchase price minus sale price, $31 minus sale price, your purchase price minus $8.25, or $22.75 per share.

• Shares Purchased On or After Aug. 4, 2021: Recognized loss is $0 under federal securities guidelines.

Transactions will be processed on a first-in, first-out (FIFO) basis. If the total valid claims submitted exceed the net cash remaining in the settlement fund, all individual payouts will be adjusted on a proportional, pro-rata basis.

Securities Laws and Why Corporate Accountability Matters

Federal securities laws, specifically the Securities Act of 1933, were established to ensure that companies issuing public stock provide complete, accurate, and honest disclosures to the public. When corporations present an overly optimistic picture or conceal known product defects during an initial public offering, individual investors bear the financial risk while company insiders and underwriters benefit.

Securities class actions are one of the most effective tools available for everyday people to challenge powerful financial institutions. Individual retail investors rarely have the financial resources or legal machinery required to take on Wall Street underwriting banks or venture capital firms single-handedly.

By pooling claims together in a class action, shareholders can force corporate leaders and financial institutions to take responsibility for misleading public filings.

Because Zymergen declared bankruptcy in 2023, recovering money directly from the corporate treasury was impossible for aggrieved shareholders. This $125 million settlement demonstrates the vital role of securities litigation: holding individual corporate officers, board directors, venture backers, and investment underwriters accountable even when the company itself falters.

Step-by-Step Guide to Filing Your Settlement Claim

To share in the $125 million settlement, you must submit a completed claim form along with supporting documentation showing your Zymergen stock purchases and sales. You do not need to hire an attorney independently to participate in this cash distribution.

Follow these simple steps to ensure your claim is filed correctly:

1. Gather Your Records: Locate your brokerage statements, transaction trade confirmation slips, or tax documents reflecting your Zymergen trades between April 21, 2021, and August 4, 2021.

2. Document Required Trading Info: You will need to state the number of shares held prior to April 20, 2021, exact trade dates, total purchase prices, sale dates, total proceeds, and the total shares held at the close of trading on August 4, 2021.

3. Submit Online or by Mail: The fastest way to file is online through the official settlement website at zymergensecuritieslitigation.com. Alternatively, you can download a PDF claim form and mail it directly to:

   Zymergen Securities Litigation

   Claims Administrator

   c/o Verita Global

   P.O. Box 301135

   Los Angeles, CA 90030-1135

4. Include Identification: You must provide the last four digits of your Social Security number or your full Taxpayer Identification Number (TIN) for tax and verification purposes.

If you have questions about filing or need assistance locating your trading records, you can call the claims administrator toll-free at 888-858-5903 or email info@ZymergenSecuritiesLitigation.com.